-
Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development
•
China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN) to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The collaboration grants AstraZeneca an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform…
-
Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges
•
China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused on developing innovative therapies to address key challenges in current obesity treatment, including muscle preservation and long-term efficacy. This move underscores Harbour BioMed’s commitment to expanding its presence in the global obesity treatment market. Technological…
-
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer to Lead Global Growth
•
China-based Harbour BioMed (HKG: 2142) announced the appointment of Michael D. Patten as Chief Strategy Officer. Based in the United States, Michael will report directly to Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. This strategic move aims to enhance Harbour BioMed’s global influence and business expansion. Role…
-
Nona Biosciences Launches Hu-mAtrIx: AI-Driven Engine for Accelerated Antibody Drug Discovery
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced the introduction of Hu-mAtrIx, an innovative AI-assisted drug discovery engine. This platform marks a significant advancement in the field of antibody development, leveraging cutting-edge technology to enhance efficiency and success rates. Integrated Antibody Discovery PlatformNona’s Hu-mAtrIx platform enables…
-
Harbour BioMed Licenses HAT001/HBM9013 to Global Partner for CRH-Targeted Therapy
•
China-based Harbour BioMed (HKG: 2142) announced a strategic collaboration and licensing agreement with an undisclosed partner to advance the development of HAT001/HBM9013, a novel corticotropin releasing hormone (CRH) targeted therapy. The alliance aims to promote the drug’s development globally, excluding Greater China. Agreement DetailsUnder the agreement, the partner will hold…
-
Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development
•
China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial intelligence (AI)-driven biotech firm. The collaboration aims to leverage their respective strengths in antibody discovery and AI to accelerate the development of innovative therapeutic antibodies. Partnership DetailsThe partnership combines Harbour BioMed’s industry-leading technology platform, proprietary…
-
Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to support research in B cell development. Agreement DetailsUnder the agreement, Dr. James Kobie of UAB will receive a non-exclusive license to develop fully human…
-
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
•
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National Medical Products Administration (NMPA) for its investigational drug HBM9378/SKB378, also known as WIN378. This fully human antibody targets thymic stromal lymphopoietin (TSLP) and is intended for the treatment of chronic obstructive pulmonary disease (COPD). Drug…
-
Nona Biosciences Partners with Invetx for Animal Health Therapies
•
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership with US-based animal health company Invetx, Inc. Under the agreement, Invetx will utilize Nona’s HCAb Harbour Mice platform to develop next-generation biological therapies for animal health. Financial details of the partnership were not disclosed. Significance…
-
Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
•
Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered into a license agreement with Switzerland-based drug developer Windward Bio AG. Windward Bio, which officially launched with a USD 200 million Series A financing round, has been granted global rights to HBM9378/SKB378, an anti-thymic stromal…
-
Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with US-based Kodiak Sciences lnc. (NASDAQ: KOD) in a strategic partnership aimed at advancing the discovery of novel multi-target antibodies to treat ophthalmic diseases. The collaboration will leverage Nona Bio’s proprietary Harbour Mice fully human antibody…
-
Harbour BioMed’s Innovative Antibody Porustobart Shows Promise in Early Clinical Trials for Melanoma
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the publication of the Phase I clinical study results for its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ PD-1 inhibitor toripalimab. This combination is aimed at treating advanced…
-
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed. Nona Bio’s HCAb…
-
Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic partnership with U.S. biotechnology company Alkyon Therapeutics, Inc. (AlkyonTx). The collaboration aims to develop next-generation immunotherapy and other targeted therapy applications, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The financial details of the…
-
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has reported a decline in its financial performance for the first half of 2024. The company’s overall revenues have dropped by 42.2% year-on-year to RMB 168 million (USD 23.7 million), with profits…
-
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic collaboration with US-based Umoja Biopharma to co-develop multi-target antibody therapies. The partnership will leverage Nona’s proprietary fully human heavy chain only antibody (HCAb) technology to create innovative CAR-T cell therapy drug candidates generated in vivo.…
-
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic cooperation agreement with Alaya.bio, a France-based polymer delivery platform company. This collaboration aims to harness their respective strengths to streamline the development, manufacturing, and administration of chimeric antigen receptor (CAR)-T therapies through precision targeting and…
-
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands, and Suzhou, China, has announced the resubmission of a biological license application (BLA) to China’s National Medical Products Administration (NMPA) for its drug candidate batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). Batoclimab…
-
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
•
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies. Under the terms of the agreement, AstraZeneca will…
-
Harbour BioMed Reports Triple-Digit Revenue Growth and First-Ever Net Profit in 2023 Financial Results
•
Harbour BioMed (HKG: 2142), a biopharmaceutical company with a global presence in Suzhou, China, Cambridge in the US, has announced its financial results for the full year of 2023. The company reported a significant leap in revenues, reaching USD 89.5 million, which marks an increase of 119.9% year-on-year (YOY). In…
